TVCMALL
12.3.2023 08:16:39 CET | Business Wire | Pressemeddelelse
Nylig blev Mobile World Congress (MWC) 2023 afholdt i Barcelona, og det var en stor succes. Mere end 88 000 deltagere og 2400+ udstillere deltog i denne begivenhed, herunder mange leverandører af mobiltelefontilbehør og grossister. Som Europas førende one-stop-shop for mobiltilbehør og engros/integreret forsyningskædeserviceplatform, TVCMALL deltaget også i dette digitale/mobile arrangement. TVCMALL, der er baseret i Shenzhen, Kina, som er verdens elektroniske center, tilbyder kunder en B2B mobiltilbehør engros-, sourcing- og tilpasningsløsning. Forskellige klassiske mobiltelefoncovers med læderfinish, opladere med multifunktioner og Amorus bærbare karaokehøjtalere fra TVCMALL fik stor ros af de fremmødte.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20230307005694/da/
TVCMALL brings one-stop wholesale solution to MWC 2023 (Photo: Business Wire)
MWC er en af verdens vigtigste telekommunikations- og teknologimesser. I løbet af de sidste 4 dage er aspekter som den seneste trend inden for mobilteknologi inklusive intelligent udstyr, 5G-netværk, AI og digitalisering blevet introduceret og delt med resten af verden.
Under showet mødte TVCMALL mange gamle kunder og mange nye venner. Mange af dem er som følger:
- Top forhandlere og distributører af mobiltelefontilbehør online
- B2C platform sælgere, Dropshippere
- Fysiske butikker, supermarkedssælgere, teleselskaber
- Gave-Tilpasningskunder (især for myndigheder, virksomheder, skoler og andre offentlige ydelser)
- OEM & ODM & OBM kunder
- Detail & Mobiltelefon værksteder
Mange kunder har samarbejdet med TVCMALL i over ti år siden etableringen i 2008, og de er vokset og udviklet sig hurtigt med TVCMALL. De udtrykte deres store påskønnelse og store taknemmelighed til TVCMALL for at levere en one-stop shop til engros, sourcing, tilpassede tjenester og andre forsyningskædetjenester.
Hvorfor de vælger TVCMALL som énuundgåelig og vigtig langsigtet partner? Fordi TVCMALL tilbyder et komplet produktkatalog med mere end 600.000 SKU'er online, og hver uge opdateres 6.000 nye produkter. Engros-processen, marketingsupport og kundeservice er effektive. TVCMALL har gode intentioner om at vokse sammen med sine kunder.
TVCMALLs omfattende anskaffelsesomkostninger er relativt lave, servicekonsistens og stabilitet er meget stærk. Derfor foretrækker mange kunder one-stop-tjenesteudbydere som TVCMALL.
Under MWC har TVCMALL etableretgod kontakt med nogle fremragende produktleverandører og e-handelstjenesteudbydere (af mobile, 3C elektroniske enheder og tilbehør).
Ii den nærmeste fremtid, med kontinuerlig TVCMALL brand og platform opgradering, vil TVCMALL styrke sit mål, "At hjælpe iværksættere med at realisere deres drømme om at lancere og opretholde en succesfuld detailforretning", og vil overholde sin forretningsdriftsfilosofi "Together we thrive". Med hensyn til specifikke strategier vil TVCMALL følge de 4 følgende anvisninger:
- Platform branding —Betjen TVCMALL-platformen som et fremtidigt århundrede gammelt brand
- Produktisering af tjenesterne - alle tjenester fra TVCMALL sammen med ideen om produktisering.
- ProduktDyb pløjning — For at være den bedste skal du trives.
- Lokalisering af TVCMALL-tjenesten — Gå globalt og lokalisere: Start lokalt marketing- og serviceteam, dybdegående forståelse og effektiv service.
TVCMALL vil se dig igen i Barcelona 2024!
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20230307005694/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum